HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Iglesias, P. Articles by Díez, J. J Search for Related Content PubMed PubMed Citation Articles by Iglesias, P. Articles by Díez, J. J

Peroxisome proliferator-activated receptor gamma agonists in renal disease

Department of Endocrinology, Hospital General, Segovia, Spain and ¹ Hospital Ramón y Cajal, Madrid, Spain

(Correspondence should be addressed to P Iglesias; Email: piglesias{at}hgse.sacyl.es)

Abstract

Type 2 diabetes is a well recognised cause of chronic renal failure (CRF). Only few oral antidiabetic drugs can be used for treating type 2 diabetes in patients with CRF. Among them are repaglinide, a rapid-acting prandial insulin releaser, and peroxisome proliferator-activated receptor gamma (PPAR) agonists, such as rosiglitazone and pioglitazone. These compounds are metabolised in the liver, therefore accumulation of the drug and the risk of severe and prolonged hypoglycaemia are minimised. PPAR receptors are expressed in many tissues including the kidney. Recently, numerous healthful effects of PPAR agonists on several aspects related to renal function have been increasingly reported. These drugs have shown to possess many advantageous anti-inflammatory, haemodynamic, vascular and metabolic effects. In the present paper we have reviewed the more recent experimental studies that evaluated these potential beneficial effects of PPAR agonists on renal function and revised the results of their utilisation in patients with different degrees of renal impairment, in dialysis patients, and in patients with diabetes mellitus after kidney transplantation. Finally, tolerability and safety profile of PPAR agonists in patients with reduced glomerular filtration rate are also analysed.

This article has been cited by other articles:

				I. Miceli, D. Burt, E. Tarabra, G. Camussi, P. C. Perin, and G. Gruden Stretch reduces nephrin expression via an angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone Am J Physiol Renal Physiol, February 1, 2010; 298(2): F381 - F390. [Abstract] [Full Text] [PDF]

				G. J. Ko, Y. S. Kang, S. Y. Han, M. H. Lee, H. K. Song, K. H. Han, H. K. Kim, J. Y. Han, and D. R. Cha Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2750 - 2760. [Abstract] [Full Text] [PDF]

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]